Optimum adjuvant trastuzumab duration for human epidermal growth factor receptor-2 positive breast cancer: a network meta-analysis of randomized trials

BACKGROUND: Adjuvant trastuzumab treatment for 12 months is the standard-of-care for early HER2-positive breast cancer; however, the optimal duration is unclear. We performed a network meta-analysis (NMA) to determine the optimal treatment duration. METHODS: We identified 16 randomized controlled tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Ji, Tang, Xiaofang, Hu, Qiancheng, Wang, Qingfeng, Chen, Ye, Li, Xiaofen, Luo, Ting, Cao, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799215/
https://www.ncbi.nlm.nih.gov/pubmed/35116489
http://dx.doi.org/10.21037/tcr-20-2378

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799215/
https://www.ncbi.nlm.nih.gov/pubmed/35116489
http://dx.doi.org/10.21037/tcr-20-2378

Ejemplares similares